Welcome to our dedicated page for Mira Pharma SEC filings (Ticker: MIRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mira Pharmaceuticals’ SEC paperwork can feel like a pharmacology textbook—dense risk factors on early-stage trials, frequent capital raises and complex share structures. If you’ve ever Googled “Mira Pharmaceuticals SEC filings explained simply” or asked, “where do I track Mira Pharmaceuticals insider trading Form 4 transactions?” you know how time-consuming the search can be. Stock Titan’s AI-powered summaries surface the essential numbers, milestones and red-flag disclosures in seconds, replacing hours of page-turning.
Whether you’re after the latest Mira Pharmaceuticals quarterly earnings report 10-Q filing to monitor R&D burn, want Mira Pharmaceuticals 8-K material events explained right after an FDA meeting, or need Mira Pharmaceuticals executive stock transactions Form 4 delivered in real time, our platform has you covered. Every document arrives straight from EDGAR and is paired with concise natural-language explanations, ratio tables and auto-generated comparisons. Understanding Mira Pharmaceuticals SEC documents with AI means spotting dilution clauses, patent expirations and cash-runway projections without wading through footnotes.
Investors use these insights to price upcoming IND submissions, compare quarter-over-quarter spending and benchmark peer pipelines. Want a Mira Pharmaceuticals annual report 10-K simplified? Our AI highlights trial timelines, intellectual-property positions and going-concern statements. Need a Mira Pharmaceuticals proxy statement executive compensation breakdown before the next vote? It’s already summarized, along with Mira Pharmaceuticals earnings report filing analysis and Mira Pharmaceuticals Form 4 insider transactions real-time alerts. Stop scrolling and start focusing on the decisions that matter.
Form 8-K Item 8.01 – Other Events
On 30 June 2025, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) disclosed pre-clinical data for SKNY-1, an oral therapeutic it is under definitive agreement to acquire from SKNY Pharmaceuticals. In a zebrafish model simulating human obesity and craving behaviour, six-day oral dosing produced an approximate 30 % body-weight reduction, leaving treated animals 10 % lighter than healthy controls while preserving muscle density. Metabolic indicators improved, including higher ventilation rate, normalised liver fat, and restoration of both LDL and HDL cholesterol to healthy levels without raising circulating triglycerides.
Behaviourally, SKNY-1 dose-dependently suppressed high-calorie consumption, reduced compulsive food seeking, and eliminated nicotine-seeking even under stress. The compound also normalised leptin and ghrelin and, at lower doses, reduced elevated dopamine linked to reward cravings.
The company states that these results warrant advancement into IND-enabling studies and positions SKNY-1 as a potential cornerstone asset once the acquisition closes, citing a combined obesity and smoking market opportunity exceeding US$200 billion.
The filing does not include human data, transaction financials, development costs, or projected timelines.
FAQ
What is the current stock price of Mira Pharma (MIRA)?
What is the market cap of Mira Pharma (MIRA)?
What is the core focus of Mira Pharmaceuticals?
What distinguishes Ketamir-2 from traditional ketamine?
What therapeutic areas are being addressed by Mira Pharma?
How does Mira Pharma position itself within the competitive landscape?
What is the significance of the IND application for Mira Pharma?
What role does MIRA-55 play in the company’s pipeline?
How does the company ensure the safety of its drug candidates?
What future clinical milestones are anticipated for Mira Pharma?
